2.10%
15.89%
-11.17%
-27.23%
-52.57%
-49.64%
-56.58%
AI Spotlight on NANO
Company Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer.Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
The company was incorporated in 2003 and is headquartered in Paris, France.
Market Data
| Last Price | 3.5 |
| Change Percentage | 2.10% |
| Open | 3.45 |
| Previous Close | 3.43 |
| Market Cap ( Millions) | 165 |
| Volume | 46591 |
| Year High | 7.21 |
| Year Low | 2.67 |
| M A 50 | 3.12 |
| M A 200 | 4.41 |
Financial Ratios
| FCF Yield | -0.93% |
| Dividend Yield | 0.00% |
| ROE | 283.43% |
| Debt / Equity | -225.78% |
| Net Debt / EBIDTA | 53.45% |
| Price To Book | -7.57 |
| Price Earnings Ratio | -4.93 |
| Price To FCF | -107.7 |
| Price To sales | 3.91 |
| EV / EBITDA | -4.6 |
News
- Jan -29 - Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
- Jan -21 - Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study
- Jan -21 - NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
- Jan -09 - Voting Rights and Shares Capital of the Company
- Dec -17 - NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
- Dec -11 - Voting Rights and Shares Capital of the Company
- Dec -09 - NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
- Nov -13 - Voting Rights and Shares Capital of the Company
- Nov -12 - NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
- Oct -31 - NANOBIOTIX to Participate in Multiple Investor Conferences in November
- Oct -11 - Voting Rights and Shares Capital of the Company
- Sep -18 - NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
- Sep -04 - NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
- Sep -03 - Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Aug -08 - Voting Rights and Shares Capital of the Company
- Jul -09 - Voting Rights and Shares Capital of the Company
- Jun -12 - NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
- Jun -11 - Voting Rights and Shares Capital of the Company
- Jun -02 - Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
- May -28 - NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Nanotherapeutics
Expected Growth : 15 %
What the company do ?
Nanotherapeutics from Nanobiotix S.A. is a novel approach using nanoparticles to enhance radiotherapy, increasing tumor destruction while reducing side effects.
Why we expect these perspectives ?
Nanotherapeutics from Nanobiotix S.A. growth driven by increasing adoption in cancer treatment, rising demand for targeted therapies, and advancements in nanotechnology. Strong pipeline of products, strategic partnerships, and expanding global presence also contribute to 15% growth.
Nanobiotix S.A. Products
| Product Range | What is it ? |
|---|---|
| NBTXR3 | A novel, first-in-class radioenhancer designed to increase the efficacy of radiotherapy in various types of cancer |
| NBTXR3 with anti-PD-1 | A combination therapy of NBTXR3 with anti-PD-1 checkpoint inhibitor to enhance the immune response in cancer treatment |
| Nanocarrier-based cancer therapy | A platform technology using nanoparticles to deliver chemotherapy directly to cancer cells |
| Local radiation therapy | A treatment approach using NBTXR3 to enhance the effects of local radiation therapy in cancer treatment |
Nanobiotix S.A.'s Porter Forces
Threat Of Substitutes
Nanobiotix S.A. operates in the biotechnology industry, where substitutes are limited. However, the company's focus on developing novel cancer treatments may lead to some substitution risks.
Bargaining Power Of Customers
Nanobiotix S.A.'s customers are primarily pharmaceutical companies and research institutions, which have limited bargaining power due to the company's specialized products and services.
Bargaining Power Of Suppliers
Nanobiotix S.A. relies on a few key suppliers for raw materials and equipment, which may lead to some bargaining power. However, the company's strong relationships with suppliers mitigate this risk.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants may pose a significant threat to Nanobiotix S.A.'s market share and intellectual property.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Nanobiotix S.A. faces intense rivalry from companies with similar products and services.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 104.11% |
| Debt Cost | 10.21% |
| Equity Weight | -4.11% |
| Equity Cost | 10.21% |
| WACC | 10.21% |
| Leverage | -2532.94% |
Nanobiotix S.A. : Quality Control
Nanobiotix S.A. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| MEDCL.PA | MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends … |
| GLPG.AS | Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that … |
| KURN.SW | Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. … |
| BIO3.DE | Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical … |
| BAVA.CO | Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
MedinCell
A-Score
1-Year Total Return ->
🥈
Kuros Biosciences
A-Score
1-Year Total Return ->
🥉
Galapagos
A-Score
1-Year Total Return ->
4
Bavarian Nordic
A-Score
1-Year Total Return ->
5
Biotest
A-Score
1-Year Total Return ->
6
